Troponin After Marathon and Endurance Events: When to Worry
Table of Contents
Introduction
In clinical practice, endurance events such as marathons and ultramarathons represent a level of physical stress that can produce measurable changes in cardiac biomarkers, including troponin. It is not uncommon to see elevated troponin levels following these events, which can initially raise concern given their established role in diagnosing myocardial infarction.
However, experienced clinicians often recognize that not all troponin elevations carry the same clinical significance. In the context of recent intense exercise, transient increases may reflect a physiological response rather than pathological injury—similar to what can be observed after brief episodes of tachyarrhythmia, where troponin can rise without underlying structural damage.
At the same time, clinicians must remain alert to less common but clinically important causes of troponin elevation, including conditions such as myocarditis, particularly if symptoms, systemic features, or abnormal findings are present.
In my own clinical experience, this balance—between avoiding unnecessary alarm and not overlooking clinically significant pathology—is one that comes up repeatedly. It is also the reason I chose to write this article: to help both athletes and clinicians better understand the underlying mechanisms and to approach post-exercise troponin elevations with the right level of caution and context.
That said, this distinction should never be made casually. Each case requires careful clinical evaluation, including consideration of symptoms, ECG findings, and serial biomarker measurements, before a benign interpretation can be made with confidence.
What Is Cardiac Troponin, and Why Does It Matter?
Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are proteins that form part of the contractile apparatus inside heart muscle cells. Their primary clinical role is the diagnosis of acute myocardial infarction (AMI): when cardiomyocytes are irreversibly damaged and begin to die, they release troponin into the bloodstream in quantities that modern assays can measure with exceptional precision [1].
Within the cardiomyocyte, troponin exists in two pools. The vast majority is structurally bound to the thin filament of the contractile apparatus—tropomyosin and actin. A smaller but clinically important cytosolic pool of free, unbound troponin also exists; some estimates from the recent literature suggest this fraction may account for as much as 5–10% of total cellular cTn, potentially larger than earlier figures [1]. It is from this cytosolic pool that post-exercise troponin release is proposed to predominantly originate—a key distinction from the structural breakdown that occurs in true myocardial infarction.
High-sensitivity troponin (HS-cTn) assays, now the standard of care in most clinical settings, detect troponin concentrations several-fold below what earlier-generation tests could measure. The 99th percentile upper reference limit (URL)—the diagnostic threshold for myocardial injury—is 14 ng/L for HS-cTnT in the most widely validated assay systems [2]. These ultra-sensitive platforms have transformed early MI detection but have also created a new clinical challenge: they now reliably detect exercise-induced elevations that older assays would have missed entirely.
In everyday clinical practice, cardiac troponin is one of the most frequently used laboratory tests when evaluating patients with suspected cardiac conditions. In my own work, I routinely use it in patients presenting with chest pain, where acute coronary syndrome needs to be ruled out, and I also frequently rely on it when assessing patients with arrhythmias. In addition, troponin testing is often part of the evaluation in patients with unexplained dyspnoea or other symptoms that may suggest cardiac involvement.
In most clinical settings, troponin is interpreted alongside the electrocardiogram (ECG), and together these form the foundation of the initial assessment of suspected cardiac disease. In my experience, when both are reassuring—particularly in the absence of concerning symptoms—they often provide strong evidence against acute, life-threatening cardiac conditions, although clinical judgment and, when necessary, further testing remain essential.
Another important aspect of troponin interpretation is its time-dependent rise. In practice, I am always mindful that troponin levels do not necessarily increase immediately after the onset of myocardial injury, which is why repeat testing is often required. In my clinical routine, it is common to recheck troponin levels approximately 3–4 hours after the initial sample, particularly when the timing of symptom onset is unclear. If chest pain has been ongoing for several hours prior to presentation, troponin levels are more likely to have already risen by the time of the first measurement.
From a clinical perspective, this widespread use means that elevated troponin values are encountered in a broad range of scenarios—not all of which reflect acute myocardial infarction. This is something I encounter regularly, and it reinforces how important it is to interpret troponin values in the correct clinical context.
How Common Is Troponin After Marathon and Endurance Events?
The short answer is: very common, and closely tied to event duration and intensity.
A systematic review and meta-analysis examining 16 studies and 939 marathon runners found that the pooled incidence of post-marathon cTn elevation was 51% (95% CI 33–69%) using standard-sensitivity assays [3]. The odds ratio for converting a normal pre-race troponin to an elevated post-race value was 51.84 (95% CI 16–168)—a strikingly large effect that underscores how routinely this phenomenon occurs in apparently healthy runners [3].
With high-sensitivity assays, the numbers are even more striking. In one Brighton Marathon kinetics subgroup, all participants exceeded the 99th percentile upper reference limit of 14 ng/L immediately after finishing the race. This should not be interpreted to mean that every endurance participant in every study shows the same pattern, but it illustrates how common marked post-race elevations can be with high-sensitivity assays [2]. The same broad pattern—often high prevalence of elevations with high-sensitivity assays across multiple endurance formats—has been reported consistently in the literature [1]. Notably, hemoglobin in runners and other red cell markers also shift acutely after a marathon—including changes driven by footstrike hemolysis, plasma volume shifts, and acute inflammation—which is why post-race blood work requires careful contextual interpretation across multiple markers rather than any single value in isolation.
Critically, the magnitude of troponin elevation appears to relate to relative exercise intensity and overall cardiac workload during endurance exercise [1][2]. Athletes exercising at higher relative intensity levels tend to demonstrate greater post-race elevations [2]. This has important clinical implications. Less conditioned or less experienced athletes may perform at a higher relative intensity during the same event, which can result in more pronounced troponin elevations compared with well-trained individuals [1][2].
In a clinical setting, the direction of change in troponin values is often more informative than a single measurement. In my experience, one of the key distinctions is whether troponin is rising or falling on serial testing. After intense exercise, troponin levels typically show a downward trend over time, whereas in acute myocardial infarction, values are more likely to continue rising in the early phase.
For this reason, I generally aim to confirm that troponin is clearly falling before attributing the elevation to exercise alone. If the pattern is not convincingly downward—or if there is any uncertainty—I tend to have a low threshold for further evaluation. This may include cardiology referral, cardiac imaging, or assessment of the coronary arteries, depending on the overall clinical picture.
Importantly, the diagnostic approach is highly dependent on the individual patient. In those with cardiovascular risk factors, obstructive coronary artery disease should be considered and reasonably excluded. In younger patients with a low-risk profile, a physiological explanation related to recent intense exercise is often more likely, but still requires careful assessment.
In my practice, even in otherwise healthy young patients without clear cardiovascular risk factors, an elevated troponin rarely goes entirely uninvestigated. In most cases, some form of follow-up or additional cardiac evaluation is performed—often including cardiology input or targeted imaging—to ensure that conditions such as myocarditis or other underlying pathology are not missed, regardless of whether the initial suspicion points toward an exercise-related cause.
The Mechanism: Cardiac Stress, Not Cardiac Catastrophe
To understand why troponin rises during endurance exercise, it helps to know what distinguishes this release from the cell death of a heart attack.
In acute myocardial infarction, atherothrombotic plaque rupture obstructs coronary blood flow, cardiomyocytes are starved of oxygen, cells undergo necrosis, and troponin is released as the structural apparatus of dying cells breaks down. This process is irreversible, sustained, and reflects true cell death.
Several proposed mechanisms may explain why post-exercise troponin release differs from the irreversible cardiomyocyte death of a heart attack [4]. The most widely discussed hypothesis is increased sarcolemmal permeability under sustained mechanical and metabolic stress. Hours of elevated cardiac output, heart rate, and systolic blood pressure impose substantial load on the myocardium. Under this load, the cardiomyocyte membrane may undergo transient disruptions—including cytoplasmatic blebbing and extracellular vesicle release—allowing cytosolic troponin to diffuse into the circulation without the underlying cell dying [1][4].
A second proposed mechanism involves stimulation of integrins by myocardial stretch. Integrins act as bidirectional signaling molecules; stimulating stretch-responsive integrins can mediate the transport of intact troponin molecules out of viable cardiomyocytes and may reflect activation of cellular cascades that result in cardiac hypertrophy [4].
There is also evidence that endurance exercise affects right ventricular (RV) function more than left ventricular (LV) function, possibly because the relative increase in RV wall stress with exercise is greater than in the LV [1]. This differential stress on the RV may contribute to the observed relationship between troponin elevation and exercise duration.
Current evidence does not typically demonstrate frank cardiomyocyte necrosis as the driver of exercise-induced troponin elevation. The kinetics of release—early peak, rapid clearance—are inconsistent with the necrosis pattern seen in MI, where ongoing structural degradation produces a sustained, later-peaking elevation [1][4]. Several cardiac MRI studies of endurance athletes have found no late gadolinium enhancement that can be directly attributed to a single bout of exercise, further supporting a non-necrotic mechanism [1]. The inflammatory response is a separate parallel phenomenon: CRP and other inflammation markers typically peak later—24 to 72 hours post-race—on a completely different timeline from the acute troponin curve.
In clinical practice, exercise-induced troponin release is generally not interpreted as evidence of irreversible myocardial injury. Rather, it is understood as a transient and reversible phenomenon that reflects the physiological stress placed on the heart during prolonged and intensive exercise.
In my experience, when the clinical picture is otherwise reassuring, this type of troponin elevation is not considered to imply lasting damage to the myocardium. Instead, it is more consistent with the adaptive response of the heart to increased workload. Regular endurance training is known to induce structural and functional adaptations, and in this context, transient biomarker elevations are typically viewed as part of that broader physiological response rather than as a sign of permanent harm.
Troponin After Marathon: Kinetics vs. Myocardial Infarction
The single most important clinical tool for distinguishing benign exercise-induced troponin from pathological release is serial testing and kinetic pattern.
In post-marathon athletes using HS-cTnT, troponin peaks within the first 1–3 hours after race completion—often reaching its maximum within the first hour. In the Brighton Marathon kinetics subgroup, levels remained above the myocardial necrosis threshold in 90% of runners at 6 hours post-race, falling to 22% at 24 hours [2]. This rapid rise and fall is the hallmark of the post-exercise pattern. It also has a practical implication: the timing of blood sampling relative to race finish determines almost everything about how the result looks, which is why preparation and timing for athlete blood tests matters in the endurance sports context.
This pattern stands in stark contrast to acute myocardial infarction, where troponin levels can continue to rise and often reach a peak within approximately 24 hours after symptom onset, consistent with ongoing myocardial injury [6]. In exercise-induced elevation, the sharp early peak with rapid downslope is consistent with a transient release of cytosolic unbound troponin—not the progressive structural breakdown of dying cells.
This kinetic distinction gives clinicians an evidence-based framework: a troponin that is falling on serial measurements taken 3–6 hours after race completion, in an asymptomatic athlete, follows the expected post-exercise trajectory. A troponin that is rising or plateauing at 24 hours occupies a different clinical category entirely [1][2].
In clinical practice, a downward trend in troponin levels is generally a reassuring sign. When troponin values are observed to decline during follow-up—such as in a patient under observation in the emergency setting—it often supports the interpretation of a transient and reversible process rather than ongoing myocardial injury. In contrast, many serious cardiac conditions, including acute myocardial infarction, are more likely to produce a continued rise or a more prolonged elevation over time.
For this reason, we place significant emphasis on troponin kinetics in clinical decision-making. Serial measurements allow us to better distinguish between potentially benign and more concerning patterns, although this distinction is not always absolute.
Importantly, a falling troponin alone does not definitively confirm a physiological, exercise-related cause. Transient troponin elevations with a subsequent decline can also be seen in other situations, including tachyarrhythmias. In the context of endurance events such as marathons, additional factors—such as electrolyte shifts, including increases in potassium related to muscle breakdown—may predispose to arrhythmias, which in turn can contribute to troponin release.
For this reason, a downward trend in troponin should be interpreted as a reassuring feature in the overall clinical picture, but not as definitive proof of a benign mechanism. Careful clinical assessment remains essential to exclude alternative causes.
When Is Troponin Elevation Concerning?
In practice, it is rarely possible to definitively determine that a troponin elevation is benign without appropriate evaluation, and in many cases this includes cardiology input. While an experienced clinician can often estimate the likelihood of a physiological versus pathological cause, a confident conclusion should only be made once more serious conditions have been reasonably excluded.
The generally reassuring interpretation for trained athletes in good health therefore comes with important, evidence-based caveats. Several findings should prompt urgent evaluation rather than blanket reassurance.
That said, there are several practical considerations that can help guide clinical decision-making and support a more structured interpretation of troponin elevation in the context of endurance exercise.
1. Persistent or rising troponin at 24 hours
In a prospective study of 120 asymptomatic recreational cyclists completing a 91-km mountain bike race, subjects with occult obstructive coronary artery disease (CAD) had strikingly higher troponin concentrations at 24 hours post-race: cTnI at 151 ng/L (IQR 72–233) versus 24 ng/L (IQR 19–82) in those without obstructive CAD (p = 0.005) [7]. The area under the receiver operating characteristic curve for cTnT at 24 hours to detect obstructive CAD was 0.82 [7], indicating that later measurements may provide clinically relevant diagnostic information.
Prolonged troponin elevation after exercise may indicate an abnormal cardiac response to stress and has been linked to occult obstructive coronary artery disease, but the exact mechanism—whether ischemic or non-ischemic—has not been definitively established.
2. Accompanying symptoms
Chest pain, dyspnoea, presyncope, syncope, palpitations, or haemodynamic instability in the context of post-exercise troponin elevation should never be attributed to exercise physiology alone without further evaluation. Clinicians should interpret elevated post-exercise troponin values with caution if any clinical symptoms or signs of myocardial ischaemia or myocarditis are present [1]. The overall risk of cardiac arrest during a marathon is around 1 per 100,000 runners—small, but not zero [10]. In middle-aged athletes with subclinical atherosclerosis, vigorous exercise may precipitate plaque erosion or transient vasospasm, events that are clinically indistinguishable from physiological “noise” on a single troponin measurement.
In practical terms, any athlete who develops concerning symptoms during or after exercise should be evaluated carefully. In my view, these presentations should prompt a low threshold for cardiology evaluation, regardless of whether troponin levels are elevated or not, and irrespective of whether any observed elevation is thought to be exercise-related.
3. ECG abnormalities
ECG findings play a central role in the assessment of post-exercise troponin elevation. New ST-segment changes, T-wave inversions in anterior or lateral leads, or new left bundle branch block in a post-race athlete with elevated troponin represent a fundamentally different scenario from an isolated troponin elevation in an asymptomatic runner. These findings should be considered potentially serious and warrant urgent cardiac evaluation.
At the same time, high-sensitivity troponin assays are generally more sensitive for detecting myocardial injury than ECG changes alone. As a result, troponin elevations may be observed even when the ECG appears normal. However, the two modalities provide complementary information and should always be interpreted together in the clinical context.
4. Older athletes and those with cardiovascular risk factors
A landmark Circulation study of 725 older long-distance walkers (median age 61 years [IQR 54–69]) found that exercise-induced cTnI elevations above the 99th percentile independently predicted higher all-cause mortality and major adverse cardiovascular events over 43 months of follow-up, with an adjusted hazard ratio of 2.48 (95% CI, 1.29–4.78) [8]. The authors noted that this population carried a substantially higher cardiovascular risk factor burden than typical younger marathon runners—a critical caveat when applying this finding—but it unambiguously demonstrates that blanket reassurance is inappropriate in older or higher-risk participants. Monitoring tools such as HRV and resting heart rate trends can provide complementary longitudinal context when evaluating recovery and cardiac stress in these athletes.
This should not, however, be misunderstood as a reason to avoid physical activity altogether. Even in individuals with established cardiovascular disease or increased risk, appropriately guided exercise is generally considered beneficial and forms an important part of long-term cardiovascular health and rehabilitation.
In my experience, most patients—provided their condition is stable—are encouraged to remain physically active at a level appropriate to their clinical situation. Light to moderate exercise, in particular, is often both safe and therapeutic. However, this should always be individualized, and in patients with known or suspected coronary artery disease, clearance and guidance from a cardiologist are essential before engaging in more intensive activity.
Summary
Troponin elevation after endurance events such as marathons is a common and often physiological finding, particularly when interpreted in the correct clinical context. The magnitude of elevation is closely related to exercise duration and intensity, and in many cases reflects a transient, reversible response to cardiac stress rather than irreversible myocardial injury.
From a clinical perspective, the key to interpretation lies not in a single value, but in the broader picture—especially symptom profile, ECG findings, patient risk factors, and, critically, the kinetic pattern of troponin over time. A rapidly rising and falling pattern in an asymptomatic athlete is typically reassuring, whereas persistent elevation, a rising trend at 24 hours, or the presence of concerning symptoms or ECG abnormalities should prompt further investigation.
In my own clinical experience, this distinction is rarely binary. While many post-exercise troponin elevations are benign, they should not be dismissed without appropriate evaluation. Even in young, otherwise healthy athletes, follow-up and, when needed, cardiology assessment are often required to exclude conditions such as myocarditis or occult coronary disease.
Ultimately, the challenge lies in balancing two risks: over-interpreting a physiological signal and under-recognizing true pathology. Careful clinical judgment—supported by serial testing, risk stratification, and appropriate referral—remains essential in ensuring that troponin after endurance exercise is interpreted both safely and accurately.
References
- https://doi.org/10.1161/CIRCULATIONAHA.121.056208
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6437282/
- https://pubmed.ncbi.nlm.nih.gov/20663014/
- https://doi.org/10.1016/j.jacc.2010.03.037
- https://doi.org/10.1016/j.ijcard.2016.06.243
- https://doi.org/10.1161/CIRCULATIONAHA.111.023697
- https://doi.org/10.1177/2047487319852808
- https://doi.org/10.1161/CIRCULATIONAHA.119.041627
- https://doi.org/10.1007/s00395-013-0391-8
- https://doi.org/10.1056/NEJMoa1106468
